Omega Pharma (Europe), and Sienna Biotec India (API manufacturer), announced a strategic partnership in which Sienna Biotec will take a minority stake in Omega Pharma's United States operations in New York, US.
A new report from IMARC Group finds that the Indian market for both diagnostic and therapeutic antibodies is expected to grow exponentially in the coming years.
ImpactRx, the pioneer in measuring the impact of promotion on physicians' attitudes and prescribing behavior, announced today the launch of a voice capture response enhancement to their unique POP 2.0™ research tool.
"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars" February 24th 2012, Hilton London Euston Hotel, London UK.
The performance of HGH biosimilars cannot be taken as an analogue to project the uptake of other biosimilar classes as penetration rates of biosimilars in different biological classes are expected to be different from one another.
EAP English and Portuguese launches new specialist services for market research companies conducting research in Brazil - desk research support and content analysis.
On the back of improving healthcare infrastructure, increasing life expectancy, and aging population, E7 countries are anticipated to show tremendous growth in future, says RNCOS.
As AdvaCare is expanding into new markets, as well as growing our product range to meet demand in these new markets, we are interested in suitable importers and distributors joining the AdvaCare team! We are interested in qualified distributors, preferably with product registration experience, in a number of key markets.
AdvaCare is a leader in supplying Veterinary products to our importers and distributors in markets and regions throughout Africa, the Middle East, Asia, and South America. Our facilities are GMP approved and have the necessary documentation for registration in existing and new markets.
RI Technologies, established in 2006, is a premier source of market research on the Biotechnology & Healthcare sector with exclusive focus on product segments, global and regional market analysis, technology trends.
This study gives an insight into global Polylactic Acid market. The report also provides market analytic by Form, and by Applications. The market is divided by Form into Films & Sheet, Coating, Fibers and Other; and by Application into Food, Textile, Medical, and Other.
AdvantaFlex thermoplastic elastomer is now offered as molded components for biopharmaceutical manifold assembly applications. The assemblies eliminate most barbed fitting connections and their leak potential while they provide a silicone alternative. Wyes (Y), tees (T), cross (X), and reducer connectors, as well as sanitary ends and container closures, are available.
Excluding Mabthera, Roche's other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.
A new report by visiongain, a London-based business information company, predicts that world revenues for antibacterial drugs will reach $43.81bn in 2016.
A new report by visiongain predicts that revenues for disease-modifying treatments for multiple sclerosis (MS) will rise to $15.8bn annually in 2015. That analysis appears in Multiple Sclerosis Treatment: World Drug Market 2012-2022.
A new report by visiongain, a London-based business information provider, predicts that the global medical device contract manufacturing revenues will reach $95.7bn in 2021.
TTC, llc, provider of industry-wide cost benchmarking tools, and the University of the Sciences in Philadelphia (USciences) sponsored the "The State of Clinical Development Costs" conference.
Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011" is now available at Marketreportsonline.com.
Visiongain predicts that the antibody therapeutics sector will be revitalised by the approval of next-generation products this decade. Overall next-generation therapeutic antibody revenues will reach $2.3bn in 2015.
Visiongain predicts that small-molecule targeted cancer therapy revenues will reach $27.3bn worldwide in 2015. That overall market generated $20.3bn in 2010, according to Small-Molecule Targeted Cancer Therapies: World Market 2011-2021.
Satisfied Users & 
Approved Press Releases
